DK1959955T3 - Fremgangsmåde til behandling af abnorm cellevækst - Google Patents
Fremgangsmåde til behandling af abnorm cellevækstInfo
- Publication number
- DK1959955T3 DK1959955T3 DK06820997.2T DK06820997T DK1959955T3 DK 1959955 T3 DK1959955 T3 DK 1959955T3 DK 06820997 T DK06820997 T DK 06820997T DK 1959955 T3 DK1959955 T3 DK 1959955T3
- Authority
- DK
- Denmark
- Prior art keywords
- cell growth
- abnormal cell
- treating abnormal
- treating
- growth
- Prior art date
Links
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000010261 cell growth Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74276605P | 2005-12-05 | 2005-12-05 | |
| US86463706P | 2006-11-07 | 2006-11-07 | |
| PCT/IB2006/003397 WO2007066187A2 (en) | 2005-12-05 | 2006-11-23 | Method of treating abnormal cell growth |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1959955T3 true DK1959955T3 (da) | 2011-02-07 |
Family
ID=38123250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK06820997.2T DK1959955T3 (da) | 2005-12-05 | 2006-11-23 | Fremgangsmåde til behandling af abnorm cellevækst |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7825137B2 (da) |
| EP (1) | EP1959955B1 (da) |
| JP (1) | JP4619346B2 (da) |
| KR (1) | KR101026676B1 (da) |
| AR (1) | AR056832A1 (da) |
| AT (1) | ATE488237T1 (da) |
| AU (1) | AU2006323027B2 (da) |
| BR (1) | BRPI0619424B1 (da) |
| CA (1) | CA2632286C (da) |
| CY (1) | CY1110931T1 (da) |
| DE (1) | DE602006018354D1 (da) |
| DK (1) | DK1959955T3 (da) |
| IL (1) | IL191471A (da) |
| NZ (1) | NZ568654A (da) |
| PL (1) | PL1959955T3 (da) |
| PT (1) | PT1959955E (da) |
| RU (1) | RU2384331C2 (da) |
| SI (1) | SI1959955T1 (da) |
| TW (1) | TWI321050B (da) |
| WO (1) | WO2007066187A2 (da) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME01788B (me) * | 2004-08-26 | 2011-02-28 | Pfizer | Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza |
| RS52902B (sr) * | 2005-08-24 | 2014-02-28 | Eisai R & D Management Co. Ltd. | Novi piridinski derivati i pirimidinski derivati (3) |
| WO2007066185A2 (en) * | 2005-12-05 | 2007-06-14 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| US7700339B2 (en) | 2006-04-14 | 2010-04-20 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| US8168383B2 (en) | 2006-04-14 | 2012-05-01 | Cell Signaling Technology, Inc. | Gene defects and mutant ALK kinase in human solid tumors |
| ATE535520T1 (de) * | 2006-08-23 | 2011-12-15 | Eisai R&D Man Co Ltd | Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung |
| US7790885B2 (en) | 2006-08-31 | 2010-09-07 | Eisai R&D Management Co., Ltd. | Process for preparing phenoxypyridine derivatives |
| JP2009132660A (ja) * | 2007-11-30 | 2009-06-18 | Eisai R & D Management Co Ltd | 食道癌治療用組成物 |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| US20090227556A1 (en) * | 2008-01-31 | 2009-09-10 | Eisai R&D Management Co., Ltd. | Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives |
| US20110206691A1 (en) | 2008-02-15 | 2011-08-25 | Mosse Yael P | Methods and Compositions for Treating Neuroblastoma |
| WO2009103061A2 (en) * | 2008-02-15 | 2009-08-20 | The Children's Hospital Of Philadelphia | Methods and compositions for identifying, diagnosing, and treating neuroblastoma |
| EP2248810A4 (en) * | 2008-02-18 | 2011-05-25 | Eisai R&D Man Co Ltd | METHOD FOR PRODUCING A PHENOXYPYRIDINE DERIVATIVE |
| EP2143441A1 (en) * | 2008-07-08 | 2010-01-13 | Pierre Fabre Medicament | Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| CN101653607B (zh) * | 2008-08-19 | 2013-02-13 | 鼎泓国际投资（香港）有限公司 | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 |
| WO2010064300A1 (ja) * | 2008-12-02 | 2010-06-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 食道癌治療用組成物 |
| DE102009003954A1 (de) | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| ES2667049T3 (es) | 2010-02-05 | 2018-05-09 | Merck Patent Gmbh | Derivados de heteroaril-[1,8]naftiridina |
| US8378104B2 (en) * | 2010-02-11 | 2013-02-19 | OSI Pharmaceuticals, LLC | 7-aminofuropyridine derivatives |
| US8916593B2 (en) | 2010-05-04 | 2014-12-23 | Pfizer Inc. | Alkoxy-substituted 2-aminopyridines as ALK inhibitors |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| ES2535656T3 (es) | 2010-07-05 | 2015-05-13 | Merck Patent Gmbh | Derivados de bipiridilo útiles para el tratamiento de enfermedades inducidas por quinasas |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| EP2680843A4 (en) * | 2011-03-03 | 2015-05-06 | Concert Pharmaceuticals Inc | DERIVATIVES OF PYRAZOLSUBSTITUTED AMINO-HETEROARYL COMPOUNDS |
| US9145390B2 (en) | 2011-03-03 | 2015-09-29 | Concert Pharmaceuticals, Inc. | Derivatives of pyrazole-substituted amino-heteroaryl compounds |
| ES2542647T3 (es) | 2011-03-09 | 2015-08-07 | Merck Patent Gmbh | Derivados de pirido[2,3 b]pirazina y sus usos terapéuticos |
| WO2013041038A1 (en) * | 2011-09-21 | 2013-03-28 | Teligene Ltd. | Pyridine compounds as inhibitors of kinase |
| TWI537259B (zh) | 2012-01-31 | 2016-06-11 | 第一三共股份有限公司 | 吡啶酮衍生物 |
| DK2822953T5 (da) | 2012-03-06 | 2017-09-11 | Pfizer | Makrocykliske derivater til behandling af proliferative sygdomme |
| WO2013148537A1 (en) * | 2012-03-29 | 2013-10-03 | Ning Xi | Substituted spirobicyclic compounds and methods of use |
| ES2655842T3 (es) | 2012-04-18 | 2018-02-21 | Cell Signaling Technology, Inc. | EGFR y ROS1 en el cáncer |
| CN103509008A (zh) * | 2012-06-22 | 2014-01-15 | 康瑟特制药公司 | 吡唑取代的氨基-杂芳基化合物的衍生物 |
| WO2014020467A2 (en) | 2012-07-30 | 2014-02-06 | Fresenius Kabi Oncology Ltd | Process for the preparation of pyrazole substituted aminoheteroaryl compounds |
| AU2013318618B2 (en) | 2012-09-24 | 2017-04-06 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (ALK) as a marker |
| WO2014071832A1 (en) * | 2012-11-06 | 2014-05-15 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
| WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| EA201201654A1 (ru) * | 2012-12-28 | 2014-06-30 | Ооо "Эн.Си.Фарм" | Противоопухолевое средство (варианты) |
| WO2014115169A2 (en) * | 2013-01-24 | 2014-07-31 | Hetero Research Foundation | Crizotinib solid dispersion |
| JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
| JP2016510787A (ja) * | 2013-03-13 | 2016-04-11 | ラシオファルム ゲーエムベーハー | クリゾチニブを含む剤形 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| JP6291179B2 (ja) * | 2013-07-26 | 2018-03-14 | 関東化學株式会社 | 光学活性２級アルコールの製造方法 |
| WO2015036898A2 (en) * | 2013-09-10 | 2015-03-19 | Shilpa Medicare Limited | Novel salts of crizotinib and their preparation |
| RU2550346C2 (ru) | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| US20160280798A1 (en) | 2013-11-06 | 2016-09-29 | The United States Of America, As Represented By The Secretary Department Of Health & Human Service | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| TWI723572B (zh) | 2014-07-07 | 2021-04-01 | 日商第一三共股份有限公司 | 具有四氫吡喃基甲基之吡啶酮衍生物及其用途 |
| JP2017530950A (ja) | 2014-08-25 | 2017-10-19 | ファイザー・インコーポレイテッド | 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用 |
| MX394386B (es) | 2014-08-28 | 2025-03-24 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
| MX385403B (es) | 2015-02-25 | 2025-03-18 | Eisai R&D Man Co Ltd | Método para suprimir el amargor de un derivado de quinoleína. |
| KR20250020678A (ko) | 2015-03-04 | 2025-02-11 | 머크 샤프 앤드 돔 엘엘씨 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
| WO2017030161A1 (ja) | 2015-08-20 | 2017-02-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| JP2018529719A (ja) | 2015-09-30 | 2018-10-11 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ |
| US12066428B2 (en) * | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| SI3458053T1 (sl) | 2016-05-20 | 2022-04-29 | Biohaven Therapeutics Ltd. | Uporaba riluzola, predzdravil riluzola ali analogov riluzola z imunoterapijami za zdravljenje rakov |
| GB201616116D0 (en) * | 2016-09-22 | 2016-11-09 | Astrazeneca Ab | Use of c-Met inhibitors to treat cancers harbouring MET mutations |
| EP3581183B1 (en) | 2017-02-08 | 2023-11-29 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
| CN108047231B (zh) * | 2018-01-02 | 2020-02-11 | 江苏医药职业学院 | [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用 |
| IT201800003875A1 (it) | 2018-03-22 | 2019-09-22 | Metis Prec Medicine Sb S R L | Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi |
| AU2020326612B2 (en) | 2019-08-02 | 2025-10-23 | Onehealthcompany, Inc. | Treatment of canine cancers |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4725601A (en) | 1985-06-04 | 1988-02-16 | Fujisawa Pharmaceutical Co., Ltd. | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers |
| GB9201693D0 (en) | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| JPH07109260A (ja) | 1993-10-12 | 1995-04-25 | Fuji Photo Film Co Ltd | ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法 |
| EP0817775B1 (en) * | 1995-03-30 | 2001-09-12 | Pfizer Inc. | Quinazoline derivatives |
| SE9700661D0 (sv) | 1997-02-25 | 1997-02-25 | Astra Ab | New compounds |
| SE9801526D0 (sv) | 1998-04-29 | 1998-04-29 | Astra Ab | New compounds |
| GB9908410D0 (en) | 1999-04-13 | 1999-06-09 | Pfizer Ltd | Pyridines |
| PT1169038E (pt) * | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| AU5636900A (en) | 1999-06-30 | 2001-01-31 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| DE60114153T2 (de) | 2000-02-16 | 2006-07-06 | Neurogen Corp., Branford | Substituierte arylpyrazine |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
| US6992087B2 (en) | 2001-11-21 | 2006-01-31 | Pfizer Inc | Substituted aryl 1,4-pyrazine derivatives |
| JP4695588B2 (ja) * | 2003-02-26 | 2011-06-08 | スージェン， インク． | プロテインキナーゼ阻害剤としてのアミノヘテロアリール化合物 |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| CN1984651A (zh) * | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物 |
| ME01788B (me) * | 2004-08-26 | 2011-02-28 | Pfizer | Enantiomerno čista aminoheteroaril jedinjenja kao inhibitori protein kinaza |
| CA2578075A1 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
| GEP20094845B (en) * | 2004-08-26 | 2009-11-25 | Pfizer | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
| WO2007066185A2 (en) * | 2005-12-05 | 2007-06-14 | Pfizer Products Inc. | Polymorphs of a c-met/hgfr inhibitor |
-
2006
- 2006-11-23 DK DK06820997.2T patent/DK1959955T3/da active
- 2006-11-23 SI SI200630864T patent/SI1959955T1/sl unknown
- 2006-11-23 PL PL06820997T patent/PL1959955T3/pl unknown
- 2006-11-23 CA CA2632286A patent/CA2632286C/en active Active
- 2006-11-23 BR BRPI0619424-9A patent/BRPI0619424B1/pt active IP Right Grant
- 2006-11-23 US US12/095,114 patent/US7825137B2/en active Active
- 2006-11-23 NZ NZ568654A patent/NZ568654A/en unknown
- 2006-11-23 RU RU2008122471/14A patent/RU2384331C2/ru active
- 2006-11-23 WO PCT/IB2006/003397 patent/WO2007066187A2/en not_active Ceased
- 2006-11-23 AU AU2006323027A patent/AU2006323027B2/en active Active
- 2006-11-23 DE DE602006018354T patent/DE602006018354D1/de active Active
- 2006-11-23 EP EP06820997A patent/EP1959955B1/en active Active
- 2006-11-23 AT AT06820997T patent/ATE488237T1/de active
- 2006-11-23 KR KR20087016376A patent/KR101026676B1/ko active Active
- 2006-11-23 PT PT06820997T patent/PT1959955E/pt unknown
- 2006-12-04 JP JP2006327355A patent/JP4619346B2/ja active Active
- 2006-12-04 TW TW095145034A patent/TWI321050B/zh active
- 2006-12-05 AR ARP060105369A patent/AR056832A1/es not_active Application Discontinuation
-
2008
- 2008-05-15 IL IL191471A patent/IL191471A/en active IP Right Grant
-
2010
- 2010-11-24 CY CY20101101055T patent/CY1110931T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2632286A1 (en) | 2007-06-14 |
| AU2006323027A1 (en) | 2007-06-14 |
| US7825137B2 (en) | 2010-11-02 |
| HK1126121A1 (en) | 2009-08-28 |
| AU2006323027B2 (en) | 2012-08-02 |
| CA2632286C (en) | 2011-11-15 |
| WO2007066187A2 (en) | 2007-06-14 |
| JP4619346B2 (ja) | 2011-01-26 |
| CY1110931T1 (el) | 2015-06-10 |
| NZ568654A (en) | 2012-02-24 |
| BRPI0619424A2 (pt) | 2011-10-04 |
| PL1959955T3 (pl) | 2011-04-29 |
| US20080300273A1 (en) | 2008-12-04 |
| JP2007153894A (ja) | 2007-06-21 |
| AR056832A1 (es) | 2007-10-24 |
| EP1959955B1 (en) | 2010-11-17 |
| PT1959955E (pt) | 2011-01-04 |
| IL191471A (en) | 2013-03-24 |
| DE602006018354D1 (de) | 2010-12-30 |
| BRPI0619424B1 (pt) | 2022-02-08 |
| RU2384331C2 (ru) | 2010-03-20 |
| WO2007066187A3 (en) | 2008-01-17 |
| SI1959955T1 (sl) | 2011-02-28 |
| RU2008122471A (ru) | 2009-12-10 |
| KR101026676B1 (ko) | 2011-04-04 |
| ATE488237T1 (de) | 2010-12-15 |
| TW200727899A (en) | 2007-08-01 |
| EP1959955A2 (en) | 2008-08-27 |
| TWI321050B (en) | 2010-03-01 |
| KR20080072965A (ko) | 2008-08-07 |
| IL191471A0 (en) | 2009-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1959955T3 (da) | Fremgangsmåde til behandling af abnorm cellevækst | |
| DK2072600T3 (da) | Fremgangsmåde til at forbedre jord | |
| DK2208469T3 (da) | Fremgangsmåde til fremstilling af en ortopædisk skæreblok | |
| DK3725329T3 (da) | Fremgangsmåde til hæmning af knogleresorption | |
| DK2135664T3 (da) | Fremgangsmåde til behandling af emissionsgas | |
| EP2184345A4 (en) | CELL SCREENING PROCESS | |
| DK1948852T3 (da) | Hovedelektrode og fremgangsmåde til dannelse af hovedelektroden | |
| PL2343362T3 (pl) | Udoskonalony sposób hodowania komórek | |
| DK3428148T3 (da) | Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf | |
| DK2445912T3 (da) | Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme | |
| DK1940250T3 (da) | Fremgangsmåde til stimulering af tarmfloraen | |
| BRPI0716528A2 (pt) | mÉtodo de estabilizaÇço | |
| DK1907628T3 (da) | Kunstgræsstruktur og fremgangsmåde til fremstilling deraf | |
| DK2342346T3 (da) | Thermotoga til behandling af biomasse | |
| DK2080808T3 (da) | Fremgangsmåde til fremstilling af l-aminosyre | |
| EP2132570A4 (en) | SCREENING PROCESS | |
| DK2079843T3 (da) | Fremgangsmåde til fremstilling af biogas | |
| EP2118273A4 (en) | METHOD FOR MODIFYING CELLS | |
| DK1850662T3 (da) | Fremgangsmåde til forbedring af nematodetolerant eller- resistent plantevækst | |
| DK2441462T3 (da) | Fremgangsmåde til behandling af type I-diabetes | |
| DK2131841T3 (da) | Fremgangsmåder til behandling af akut smerte | |
| DK1952103T3 (da) | Fremgangsmåde til at veje med flere vejeceller | |
| ZA200804777B (en) | Method of treating abnormal cell growth | |
| EP1953224A4 (en) | METHOD FOR MODIFYING A CHROMOSOME | |
| EP1946857A4 (en) | PROCESS FOR MODIFYING ASBESTOS |